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Abstract
The acquisition of neuraminidase (NA) inhibitor resistance by H5N1 influenza viruses has serious clinical implications, as this
class of drugs can be an essential component of pandemic control measures. The continuous evolution of the highly
pathogenic H5N1 influenza viruses results in the emergence of natural NA gene variations whose impact on viral fitness and
NA inhibitor susceptibility are poorly defined. We generated seven genetically stable recombinant clade 2.2 A/Turkey/15/06-
like (H5N1) influenza viruses carrying NA mutations located either in the framework residues (E119A, H274Y, N294S) or in
close proximity to the NA enzyme active site (V116A, I117V, K150N, Y252H). NA enzyme inhibition assays showed that NA
mutations at positions 116, 117, 274, and 294 reduced susceptibility to oseltamivir carboxylate (IC50s increased 5- to 940-
fold). Importantly, the E119A NA mutation (previously reported to confer resistance in the N2 NA subtype) was stable in the
clade 2.2 H5N1 virus background and induced cross-resistance to oseltamivir carboxylate and zanamivir. We demonstrated
that Y252H NA mutation contributed for decreased susceptibility of clade 2.2 H5N1 viruses to oseltamivir carboxylate as
compared to clade 1 viruses. The enzyme kinetic parameters (Vmax,K m and Ki) of the avian-like N1 NA glycoproteins were
highly consistent with their IC50 values. None of the recombinant H5N1 viruses had attenuated virulence in ferrets
inoculated with 10
6 EID50 dose. Most infected ferrets showed mild clinical disease signs that differed in duration. However,
H5N1 viruses carrying the E119A or the N294S NA mutation were lethal to 1 of 3 inoculated animals and were associated
with significantly higher virus titers (P,0.01) and inflammation in the lungs compared to the wild-type virus. Our results
suggest that highly pathogenic H5N1 variants carrying mutations within the NA active site that decrease susceptibility to
NA inhibitors may possess increased virulence in mammalian hosts compared to drug-sensitive viruses. There is a need for
novel anti-influenza drugs that target different virus/host factors and can limit the emergence of resistance.
Citation: Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA (2010) Effect of Neuraminidase Inhibitor–Resistant Mutations on Pathogenicity of Clade 2.2
A/Turkey/15/06 (H5N1) Influenza Virus in Ferrets. PLoS Pathog 6(5): e1000933. doi:10.1371/journal.ppat.1000933
Editor: Ron A. M. Fouchier, Erasmus Medical Center, Netherlands
Received October 23, 2009; Accepted April 28, 2010; Published May 27, 2010
Copyright:  2010 Ilyushina et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human
Services, under Contract No. HHSN266200700005C, and by the American Lebanese Syrian Associated Charities (ALSAC). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors declare no competing financial interests. While the study reported here did not utilize corporate funding, Drs. Natalia A.
Ilyushina, Elena A. Govorkova, and Robert G. Webster are currently performing a different research study funded by F. Hoffmann-LaRoche, Ltd., Basel, Switzerland.
In addition, the NA inhibitors oseltamivir carboxylate and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland).
* E-mail: elena.govorkova@stjude.org
Introduction
The highly pathogenic avian H5N1 influenza viruses remain of
concern as a pandemic threat. Of the 486 cases of human H5N1
infection confirmed between March 2003 and March 2010,
,60% were lethal [1]. The H5N1 influenza viruses have
continuously evolved and increased in genetic diversity: to date,
10 H5 hemagglutinin (HA) clades have been distinguished, some
of which are geographically widespread [2]. The most epidemi-
ologically significant clades are 1, 2 (subclades 2.1, 2.2, 2.3), and 7
[3].
Although vaccination remains the primary method of influenza
control, effective antiviral drugs are the best option when vaccine
availability or efficacy is limited [4]. The anti-influenza drugs,
neuraminidase (NA) inhibitors (oseltamivir and zanamivir) [5], are
sialic acid analogues that selectively target the NA enzyme of
influenza A and B viruses [6,7]. Both are safe and effective for the
prophylaxis and treatment of seasonal H1N1 and H3N2 influenza
[5]. There is limited information about the clinical use of NA
inhibitors against highly pathogenic H5N1 influenza viruses;
however, studies in animal models suggest their efficacy [8–10].
The orally administered NA inhibitor oseltamivir was chosen for
stockpiling for the national pandemic preparedness plan.
In the event of a pandemic, the effectiveness of therapeutic and
prophylactic oseltamivir will depend not only on the correct
dosage and duration of treatment but also on the susceptibility of
the targeted virus strain. Our group [9,10] and others [11] have
shown that the NA inhibitor susceptibility of H5N1 viruses of
clades 1 and 2.2 may differ. We found an 18-fold difference
between the in vitro oseltamivir carboxylate (the active methabolite
of oseltamivir) susceptibility of A/Turkey/15/06 (H5N1) virus
(clade 2.2) and A/Vietnam/1203/04 (H5N1) virus (clade 1) and
different treatment efficacy in mice inoculated with these viruses
(20% vs. 80% survival on the same regimen) [8,9]. Recent data
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decrease the in vitro susceptibility of H5N1 influenza viruses to
oseltamivir carboxylate [10–13], possibly reducing the efficacy of
the drug in vivo. These findings demonstrate the need for
systematic evaluation of the impact of natural NA gene variations
on anti-NA drug susceptibility and on other biological properties
of H5N1 influenza viruses.
Oseltamivir and zanamivir were designed to bind only to highly
conserved residues within the active site of influenza A and B virus
NA protein [6]. This active site comprises 8 functional residues
(R118, D151, R152, R224, E276, R292, R371, and Y406; N2
numbering here and throughout) and 11 framework residues
(E119, R156, W178, S179, D198, I222, E227, H274, E277, N294,
and E425) [14]. Despite a high degree of conservation of these
residues, the NA substitutions identified in NA inhibitor-resistant
influenza viruses isolated both in vitro and clinically tend to be NA
subtype–specific: E119A/G/D/V, R292K, and N294S in the N2
and N9 subtypes and H274Y and N294S in the N1 subtype
[14,15]. Broad screening of the in vitro susceptibility of seasonal
and H5N1 influenza viruses to NA inhibitors together with recent
crystal structure data and conformational studies of influenza N1
enzyme identified several additional conserved or semiconserved
NA residues (e.g., V116, I117, Q136, K150, D151, and I222) that
may also confer resistance [12,16–19]. Importantly, the exact
mechanism by which these changes affect susceptibility to a
particular NA inhibitor are not yet understood.
Early studies suggested that seasonal influenza viruses resistant
to NA inhibitors may be less infective and transmissible in ferrets
than their wild-type counterparts [20–22]. The two available
reports on the fitness of highly pathogenic oseltamivir-resistant
H5N1 viruses of clade 1 offered different findings [23,24]. In
ferrets, an oseltamivir-resistant H5N1 virus carrying an H274Y
NA mutation replicated approximately 10 times less efficiently in
the upper respiratory tract than the wild-type virus [23]. In
contrast, neither the H274Y nor the N294S NA mutation
compromised the lethality or virulence of clade 1 A/Vietnam/
1203/04 (H5N1) virus in mice [24]. This difference in fitness may
reflect a difference in virulence, although the question remains to
be answered.
In the homogeneous clade 2.2 A/Turkey/15/06-like (H5N1)
genetic background, we studied the role of single point NA
mutations near or within the enzyme active site on NA inhibitor
susceptibility, NA enzyme kinetics, viability, genetic stability, and
pathogenesis in ferrets. Seven substitutions were stable in the N1
NA protein and five reduced virus susceptibility to oseltamivir
carboxylate or to both NA inhibitors. Infection of ferrets with the
recombinant H5N1 viruses caused mild disease of various
duration, although NA inhibitor-resistant variants with the
E119A and N294S mutations were more virulent than the wild-
type virus.
Results
Generation, Growth, and Genetic Stability of
Recombinant H5N1 Viruses
We used the eight-plasmid reverse genetics technique to
generate 11 recombinant A/Turkey/15/06-like (H5N1) viruses
carrying different NA mutations (Figure 1), that were proposed to
affect virus susceptibility to NA inhibitors [12,16–19]. Two NA
mutations (H274Y and N294S) were selected based on case
reports on the isolation of oseltamivir-resistant variants in H5N1
virus infected patients after treatment with oseltamivir [23,25] or
before administration of the drug [26]. Four NA residues (R111,
S247, Y252, and D283) were chosen based on the differences of
amino acid alignments of the NA active sites of A/Vietnam/1203/
04 (H5N1) virus (clade 1) and A/Turkey/15/06 (H5N1) virus
(clade 2.2) (data not shown). Five NA residues (V116, I117, E119,
K150, and I222) were selected based on the results of NA enzyme
inhibition assays that substitutions at these positions may be linked
to reduced drug-susceptibility in avian and human viruses carrying
N1 NA [19]. The viability of the recombinant viruses was
evaluated by rescue from transfected 293T cells. Viruses with the
R111K, I222L, S247N, and D283N NA amino acid substitutions
could not be rescued in three independent experiments, clearly
indicating that these mutations are not stably maintained in the
clade 2.2 A/Turkey/15/06-virus background.
The recombinant wild-type (WT) H5N1 influenza virus and
seven mutants (V116A, I117V, E119A, K150N, Y252H, H274Y,
and N294S) were successfully rescued. Direct sequencing of their
HA and NA genes revealed that all mutations were correctly
incorporated and no additional changes were present in either
gene (data not shown). All of the viruses grew to comparable titers
and formed homogeneous plaques in MDCK cells (diameter, 0.3
to 1.7 mm), although viruses with the Y252H, H274Y, and N294S
NA mutations formed significantly smaller plaques than did the
WT virus (P,0.01) (Table 1).
To assay the growth and genetic stability of the recombinant
viruses in vitro, we serially passaged each virus three times in
MDCK cells (Table 1). Virus yields before passaging and after the
third passage did not differ significantly. All mutants were able to
maintain their plaque phenotype with the exception of those
carrying mutations at positions 252 and 274: homogenous large
plaques were observed for both Y252H and H274Y viruses after
the third passage (Table 1). Sequence analysis after the third
passage showed that neither WT virus nor viruses carrying NA
mutations at residues 116, 117, 119, 150, 252, 274, and 294 had
acquired any additional amino acid changes in their HA or NA
genes (data not shown). Thus, our results suggested that all
introduced NA mutations remained genetically stable in A/
Turkey/15/06 (H5N1) virus background, however, the possibility
that some mutations in polymerase or other genes might occur
during in vitro passaging cannot be excluded.
Author Summary
Highly pathogenic avian H5N1 influenza viruses remain a
potential pandemic threat. If vaccination is not available in
the event of a pandemic, antiviral drugs such as
neuraminidase (NA) inhibitors (oseltamivir and zanamivir)
will be crucial for disease control. However, the emergence
of NA inhibitor–resistant virus mutations can significantly
limit the effectiveness of treatment. We used reverse
genetics techniques to study the impact of specific point
mutations in the NA gene on the pathogenicity of clade
2.2 H5N1 influenza viruses in a ferret animal model. Seven
recombinant H5N1 viruses (containing the mutations
V116A, I117V, E119A, K150N, Y252H, H274Y, and N294S)
were viable and genetically stable in MDCK cells. Three of
the NA mutations were of particular significance: (1) E119A
conferred resistance to both oseltamivir carboxylate and
zanamivir and increased virus virulence in ferrets; (2)
H274Y conferred a high level of resistance to oseltamivir
carboxylate; and (3) N294S conferred moderate level of
resistance to oseltamivir carboxylate and increased virus
virulence in ferrets. Strategies to limit the emergence of
drug resistance are urgently needed.
NA Inhibitor Resistance and H5N1 Phenotype
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Recombinant H5N1 Viruses
An NA enzyme inhibition assay, a reliable phenotypic assay
used to characterize the NA inhibitor susceptibility of influenza
viruses, showed altered susceptibility in all recombinant H5N1
influenza viruses except that with K150N substitution. The
susceptibility of V116A, I117V, and N294S viruses to oseltamivir
carboxylate or zanamivir was moderately reduced (mean IC50
increase, 5-63–fold and 3-33–fold, respectively) as compared to
that of WT virus. Virus carrying the E119A mutation was
moderately more resistant to oseltamivir carboxylate (35-fold
increase in mean IC50 value) and markedly more resistant to
zanamivir (.1200-fold increase in mean IC50 value) than was WT
virus (Table 2). The H274Y mutant was much more resistant to
oseltamivir carboxylate (mean IC50 increase, .900-fold) and
slightly less susceptible to zanamivir (mean IC50 increase, 3-fold)
than WT virus. In contrast, the Y252H NA change conferred
increased susceptibility to oseltamivir carboxylate (mean IC50
decrease, 22-fold) (Table 2).
To determine the effect of the NA mutations on viral functional
properties, we characterized their kinetic NA enzymatic param-
eters, including their Michaelis-Menten constants (Km), which
reflect NA affinity for the MUNANA substrate, their inhibition
constants (Ki) for oseltamivir carboxylate and zanamivir, and their
relative NA enzymatic activity (Vmax) (Table 2, Figure 2). NA
proteins harboring the V116A, I117V, and E119A mutations
exhibited significantly lower affinity for the substrate (mean Km
decrease, 4–8–fold) than did other NAs studied. The Ki values of
all NA glycoproteins were consistent with their IC50 values
(Table 2), suggesting that the reduced susceptibility to both NA
inhibitors could be caused by decreased affinity of their mutant
NAs to the antiviral drugs.
We also determined NA enzymatic Vmax values for each of
the recombinant H5N1 viruses (Figure 2) and calculated their
Vmax ratios in relation to that of WT NA glycoprotein (Table 2).
NA proteins with mutations at residues 117 and 252 had
significantly higher enzymatic activity than WT NA (P,0.01).
The other five NA mutations studied significantly reduced the
Figure 1. Crystal structure of the A/Vietnam/1203/04 (H5N1) NA molecule (Protein Data Bank:2HTY). Shown are 11 residues in or near
the enzyme’s active site (black) that were substituted in this study. Residues shown in purple are positions where a single amino acid substitution
affects the stability of the recombinant A/Turkey/15/06-like (H5N1) influenza virus.
doi:10.1371/journal.ppat.1000933.g001
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Vmax ratios, 0.1) (Table 2, Figure 2). Thus, the eight
recombinant H5N1 viruses differed in both their NA enzyme
kinetics and their in vitro susceptibility to oseltamivir carbox-
ylate and zanamivir.
Pathogenicity of Recombinant H5N1 Viruses in Ferrets
Limited information is available on the pathogenicity of H5N1
influenza viruses carrying various drug-resistant NA mutations in
ferrets [23], although it can be an indicator of pathogenic potential
of these viruses in humans. We inoculated ferrets with 10
6 EID50
Table 1. Growth of Recombinant H5N1 Influenza Viruses Before and After Passaging in MDCK Cells.
H5N1 recombinant virus
a Before passaging 3
rd passage
b
Virus yield (log10PFU/ml) Plaque size (mm ± SD) Virus yield (log10PFU/ml) Plaque size (mm ± SD)
WT 6.560.4 1.660.4 6.860.3 1.560.3
V116A 6.260.4 1.760.4 6.260.2 1.860.3
I117V 6.260.2 1.660.2 6.460.3 1.560.2
E119A 6.260.3 1.460.3 6.260.4 1.760.3
K150N 6.360.3 1.160.3 6.260.4 1.160.5
Y252H 6.360.3 0.860.3* 6.660.8 2.060.4u
H274Y 6.960.2 0.360.1* 6.860.5 2.760.6*,
u
N294S 6.660.3 0.860.2* 6.760.3 0.560.2*
aAmino acid numbering is based on N2 NA [43].
bMDCK cells were infected with recombinant viruses at an MOI of 0.001 PFU/ml and virus yield was determined after 72 h incubation at 37uC. Plaque size of any 10
plaques was measured by the FinescaleH comparator (Los Angeles, CA, USA). The HA and NA genes were sequenced after the 3
rd passage. The emergence of different
subpopulations indicated genetic instability.
* P,0.01 compared to WT virus from the same passage (one-way ANOVA).
u P,0.01 compared to plaque size after the first passage (unpaired two-tailed t-test).
doi:10.1371/journal.ppat.1000933.t001
Table 2. Enzymatic Properties of the Neuraminidase of Recombinant H5N1 Influenza Viruses.
H5N1
recombinant
virus Mean IC50 ± SD (nM)
a
Mean Km ± SD
(mM)b (95% CI)
Vmax
ratioc Mean Ki ± SD (nM)
d
Oseltamivir
carboxylate
Mean
fold
change Zanamivir
Mean
fold
change
Oseltamivir
carboxylate
Mean
fold
change Zanamivir
Mean
fold
change
WT 6.760.8 1.0 1.060.1 1.0 142.6641.2
(49.4–235.7)
1.0 3.960.5 1.0 0.660.1 1.0
V116A 48.462.1* 7.2* 32.860.9* 32.8* 623.7641.0*
(531.0–716.5)
0.1* 41.661.8* 10.7* 28.260.8* 47.0*
I117V 34.361.6* 5.1* 4.160.3* 4.1* 742.06139.5*
(426.4–1057.0)
4.1* 30.266.7* 7.7* 3.660.3* 6.0*
E119A 236.5655.9* 35.3* 1253.86171.5* 1253.8* 1096.0641.3*
(1002.0–1189.0)
0.1* 216.7651.3* 55.6* 1148.56157.2* 1914.2*
K150N 8.361.2 1.2 1.260.1 1.2 110.4615.5
(75.4–145.4)
0.1* 4.460.6 1.1 0.760.1 1.2
Y252H 0.360.1* 0.1* 1.360.1 1.3 199.9662.3
(59.1–340.8)
1.8* 0.260.1* 0.1* 0.960.1 1.5
H274Y 6308.061199.5* 941.5* 2.560.1* 2.5* 130.9610.5
(107.2–154.6)
0.1* 3573.56905.8* 916.3* 1.460.1* 2.3*
N294S 424.2613.5* 63.3* 3.460.3* 3.4* 298.5615.1
(234.3–332.6)
0.1* 317.6610.2* 81.4* 2.560.2* 4.2*
aNA inhibition assay was performed with viruses standardized to equivalent NA activity and incubated with NA inhibitors (0.00005–100 mM) and MUNANA substrate.
IC50 was determined by plotting the dose-response curve of inhibition of NA activity as a function of the compound concentration. Values represent 3 independent
determinations.
bKm represents a half-maximal catalytic rate. The enzyme kinetic data were fit to the Michaelis-Menten equation using GraphPad Prism 4. Values are the mean 6 SD
from one representative experiment done in triplicate.
cRatio of the respective viruses’ NA Vmax to the Vmax of WT recombinant A/Turkey/15/06 virus NA. Vmax was calculated using a nonlinear regression of the curve
according to the Michaelis-Menten equation.
dDetermined by enzymatic kinetic analysis and calculated using nonlinear regression of the plot of initial velocity as a function of inhibitor concentration.
*P,0.01 compared to WT virus (one-way ANOVA).
doi:10.1371/journal.ppat.1000933.t002
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outcome (Table 3, Figure 3). Recombinant WT virus caused mild
clinical disease signs of moderate duration, similar to those caused
by wild-type A/Turkey/15/06 (H5N1) strain [10].
Mild but prolonged illness (duration , 10 days, relative
inactivity index, RII<0.01) was seen in ferrets infected with
mutant V116A and K150N viruses (Table 3). Despite their weight
gain throughout the infection, the ferrets showed a mean peak
temperature increase of , 1.0–1.3uC on day 8 post-inoculation
(p.i.) (Figure 3A). On days 4, 6, and 8 p.i. the peak nasal
inflammatory cell counts in nasal washes was significantly higher
in groups of ferrets inoculated with V116A and K150N
recombinants than in those inoculated with WT virus (P,0.01).
Virus shedding started at 1 day p.i. for mutant viruses and
continued until 6 days p.i. Interestingly, on day 1 p.i. virus titers in
nasal washes were significantly lower for animals infected with
recombinant V116A and K150N viruses than those in animals
inoculated with WT virus (P,0.05), but remained significantly
higher on day 6 p.i. (P,0.05) (Figure 3A).
Mild, short illness (duration , 5–6 days) was observed in ferrets
inoculated with H5N1 viruses carrying I117V and Y252H NA
mutations: only slight temperature elevation (mean peak increase,
0.5 to 1.2u C), mild clinical features (RII<0.05) (Table 3) and
minor weight changes were detected (Figure 3B). Cell counts
remained at the same level in nasal washes of animals infected with
either WT or I117V viruses, and they returned to normal levels in
ferrets inoculated with Y252H at day 6 p.i. Comparison of the
protein concentrations in the nasal washes showed no significant
differences among the I117V, Y252H and WT viruses, suggesting
that upper respiratory tract inflammation in these groups was
comparable. Recombinant I117V and Y252H viruses replicated
less efficiently in the upper respiratory tract than did the WT strain
(P,0.05) (Figure 3B).
Virus with the H274Y NA mutation exhibited virulence
comparable to that of recombinant WT virus (Table 3,
Figure 3C). In contrast, inoculation of ferrets with recombinant
E119A and N294S viruses caused markedly different results.
Animals showed more pronounced clinical signs of disease,
including a slightly greater RII (<0.3–0.4), and one of three
ferrets in each group was euthanized before the end of the
experiment due to severe lethargy or excessive weight loss
(Table 3). The body temperature elevation and nasal-wash
inflammatory cell count were significantly higher in animals
inoculated with the E119A mutant than in those inoculated with
recombinant WT virus (P,0.01) (Figure 3C). The recovery of
ferrets inoculated with the N294S NA mutant was delayed, and
they regained no weight during the observation period.
To characterize in more details the disease caused by
recombinant E119A and N294S viruses, we increased the number
of animals from three to five in each of the pathogenicity groups
Figure 2. NA enzyme kinetics of the recombinant A/Turkey/15/
06-like (H5N1) viruses. Substrate conversion velocity (V0)o fN Ai s
shown as a function of substrate concentration. Fluorogenic MUNANA
substrate was used at a final concentration of 0 to 2000 mM. The viruses
were standardized to an equivalent dose of 10
7.5 PFU/ml. Fluorescence
was measured every 92 sec for 45 min at 37uC, using excitation and
emission wavelengths of 355 and 460 nm, respectively.
doi:10.1371/journal.ppat.1000933.g002
Table 3. Pathogenicity of the Recombinant H5N1 Influenza Viruses in Ferrets.
Reverse-genetics virus
Change in
oseltamivir
resistance
a
No. of
surviving/
total no.
Mean survival
time ± SD
b
Relative
inactivity
index
c
Mean serum
antibody
response
d
Mild, moderate duration
WT 1.0 3/3 .21.0 0.00 160
H274Y 941.5 3/3 .21.0 0.01 240
Mild, prolonged duration
V116A 7.2 3/3 .21.0 0.00 80
K150N 1.2 3/3 .21.0 0.02 80
Mild, short duration
I117V 5.1 3/3 .21.0 0.04 80
Y252H 0.1 3/3 .21.0 0.06 80
Severe illness
E119A 35.3 2/3 15.360.3* 0.29* 80
N294S 63.3 2/3 17.760.3* 0.46* 240
aMean fold-change in IC50 compared to that of WT virus.
bDetermined by the Kaplan-Meier method (Mantel-Haenszel test).
cDetermined once daily for 14 days of observation based on the scoring system described in Methods and was calculated as the mean score per group of ferrets per
observation (day) over the 14-day period. The relative inactivity index before inoculation was 0.
dHemagglutination inhibition (HI) titers determined in ferret sera 21 days p.i. with A/Turkey/15/06 (H5N1) virus. Data are from groups of 2 (for E119A and N294S viruses)
or 3 ferrets.
*P,0.05 compared to WT virus (one-way ANOVA).
doi:10.1371/journal.ppat.1000933.t003
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6 EID50 of the WT,
E119A, and N294S viruses (Figure S1). Importantly, all clinical
symptoms of disease were similar to those observed in the first
experiment (Figure 3C), including a slight increase in RII for the
E119A and N294S (0.3 and 0.4, respectively) and substantial
weight loss (,15%) of N294S-infected ferrets. We observed that
nasal-wash inflammatory cell counts were significantly higher in
animals infected with mutant viruses than in those infected with
WT (P,0.01) (Figure S1). Thus, in two independent experiments,
the infection of ferrets with viruses carrying E119A or N294S NA
mutations consistently caused more severe influenza disease than
WT virus. Taken together, our results showed that changes in the
Figure 3. Patterns of clinical outcome in ferrets inoculated with the recombinant A/Turkey/15/06-like (H5N1) viruses. (A) Mild,
prolonged illness, (B) mild, brief illness, and (C) severe illness or (comparable to WT) caused by the indicated recombinant viruses. Shown are change
in body temperature and weight, total number of inflammatory cells and protein concentrations in nasal washes, and virus titers in the upper
respiratory tract. The horizontal lines show the mean inflammatory cell counts and protein concentrations in the nasal washes of uninoculated
animals. Values are the mean 6 s.d. for three ferrets. The mean s.d. of all data points for change in body temperature and weight was ,64.5%.
*, P,0.05, **, P,0.01 compared to WT virus (one-way ANOVA).
doi:10.1371/journal.ppat.1000933.g003
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affect the pathogenesis of clade 2.2 A/Turkey/15/06 (H5N1)
influenza virus in ferrets.
Histopathology and Replication of Recombinant WT,
E119A, and N294S Viruses in Internal Organs of Ferrets
To identify characteristics that may explain the severity of
infection caused by E119A and N294S H5N1 mutants compared
to WT stain, we evaluated virus replication and tissue tropism in
the lungs, nasal turbinate, trachea, spleen, liver, and small intestine
of two inoculated ferrets per virus on day 4 p.i. All three viruses
were detected in the lungs, nasal turbinate, and trachea; however,
only the E119A and N294S mutants were detected in the liver
(Figure 4A). Consistent with the more pronounced clinical signs of
disease, the E119A and N294S were detected at significantly
higher titers in three out of four lobes of the lungs (,4.9–6.7
log10EID50/gram tissue) and liver (,1.7–2.9 log10EID50/gram
tissue) (P,0.01). Of the three H5N1 viruses, the N294S
recombinant yielded significantly higher virus titers in the trachea
(,6.2 log10EID50/gram tissue versus 4.7 log10EID50/gram tissue,
P,0.01) (Figure 4A).
We further histologically examined the tissues of inoculated
ferrets to investigate the lesions associated with virus replication in
infected organs and to obtain more information about the
differences in virulence between recombinant WT, E119A, and
N294S viruses. Histological changes were detected only in the
lungs of infected animals. Bronchopneumonia and bronchiolitis
with epithelial necrosis and/or regeneration characterized by
bronchiole hypertrophy and hyperplasia were observed in all
ferrets on day 4 p.i. (Figure 4B). However, the degree of severity
and the number of lung lobes showing pneumonic lesions differed
between the three groups. We determined that only two lung lobes
of both ferrets inoculated with WT virus had foci of broncho-
pneumonia. However, the ferrets inoculated with N294S recom-
binant had bronchopneumonia in , 50% of two lung lobes and in
.90% of the other two lobes. The E119A-infected animals
revealed multifocal bronchopneumonia in .90% of all four lung
lobes (Figure 4B).
Differences in the type and extent of the alveolar pathology
were also apparent on histopathologic examination. Of the three
H5N1 viruses, the E119A mutant caused very severe and extensive
alveolitis with necrosis of the alveolar pneumocytes and interstitial
septal walls resulting in the loss of the alveolar architecture and
leading to large coalescing spaces of edema fluid, fibrin,
inflammatory and hemorrhagic red blood cells (Figure 4B). In
the N294S-infected ferrets, alveolitis was characterized by a
centrifugal progression of severity from the peribronchiole alveoli
to the subpleural alveoli with pneumocyte hyperplasia and
extensive infiltrates of inflammatory cells obscuring the lace-like
alveolar pattern. In contrast, in the WT group, the peribronchiole
and peripheral alveoli had only mild to moderate inflammatory
cell infiltrates and a lace-like pattern with a slight thickening of the
alveolar interstitial septa (Figure 4B).
Additionally, to assay the genetic stability of the recombinant
viruses in vivo, we extracted RNA directly from nasal wash samples
obtained on day 6 p.i. and sequenced the NA and HA genes of the
dominant virus populations. No amino acid substitutions were
identified in the NA gene of viruses isolated from ferrets inoculated
with the WT, E119A, or N294S recombinants. A single F291L
mutation in the HA gene was identified in 1 of 3 ferrets inoculated
with either E119A or N294S mutants.
Taken together, our results indicated that the introduced E119A
and N294S NA mutations were stably maintained in A/Turkey/
15/06 (H5N1) virus background in ferrets. Further, increased
virulence and severity of disease caused by H5N1 viruses carrying
E119A and N294S NA changes were associated with higher virus
titers and more pronounced local inflammatory response in the
lungs compared to WT virus.
Discussion
Oseltamivir-resistant H1N1 influenza viruses emerged recently
and became predominant during the 2007–2008 season in the
absence of drug-selection pressure [27,28]; however, the molecular
mechanisms and viral characteristics underlying this phenomenon
are unknown. The NA inhibitors are an important component of
influenza pandemic preparedness. In the case of H5N1 influenza
viruses, genetic diversity and continuous evolution [1,2] are known
to contribute to reduced susceptibility to NA inhibitors and thus to
reduced drug efficacy. In the present study, we introduced single
point NA mutations into the A/Turkey/15/06 (H5N1)-virus
genetic background at framework and functional NA residues to
assess their effect on the NA-inhibitor resistance phenotype and on
their pathogenicity in a ferret model. Of 11 NA mutations studied,
seven located within (E119A, H274Y, and N294S) or near
(V116A, I117V, K150N, and Y252H) the enzyme active site were
stably maintained and grew to titers comparable to WT virus in
MDCK cells. Five of these 7 NA mutations (all but K150N and
Y252H) reduced H5N1 virus susceptibility either to oseltamivir
carboxylate or to both NA inhibitors.
Our most important finding is that the E119A NA substitution
in the clade 2.2 A/Turkey/15/06 (H5N1)-virus background is
viable and genetically stable and confers cross-resistance to
oseltamivir carboxylate and zanamivir. Structural analysis showed
that the glutamate at 119 is one of two conserved amino acid
residues that interact with oseltamivir’s carboxylate group to allow
a strong, specific bond between the enzyme active site and the
inhibitor [29]. The amino acid alanine has shorter side chains than
does glutamate, a difference that may impede this interaction. The
resistance of the E119A NA mutant to both zanamivir and
oseltamivir carboxylate suggests that they interact similarly with
the conserved framework residues of viral NA [29]. E119G/A/D/
V NA mutations are commonly reported to be associated with NA
inhibitor resistance and were identified in influenza viruses of the
N2 NA subtype [14,15]. Further, the E119A NA substitution has
been selected in several strains of influenza A (H4N2) and B
viruses after in vitro passages in the presence of zanamivir and has
resulted in reduced NA activity [30,31]. In a previous study, the
E119A mutant in an A/WSN/33 (H1N1)-virus background could
not be rescued [32], suggesting that this mutation may impede the
growth of H1N1 viruses more than that of H4N2 viruses.
Moreover, the E119G NA mutation significantly compromised
viral growth and was genetically unstable in a clade 1 A/Vietnam/
1203/04 (H5N1)-virus background [24]. In contrast, we recently
found that in mice, E119A mutation is stably maintained in the
NA of clade 2 H5N1 virus during oseltamivir therapy and is
associated with resistance to both NA inhibitors [13]. Our finding
that E119A reduced the NA activity of H5N1 virus 10-fold
without compromising viral yield in MDCK cells suggests that
these changes in NA activity do not compromise the infectivity of
these viruses due to their high replication ability.
In the present study, V116A and I117V mutants showed a low
(,6-fold greater than WT) level of resistance to oseltamivir
carboxylate. This finding is consistent with those of Hurt et al [12],
who indentified two H5N1 influenza isolates (A/Chicken/
Indonesia/Wates/77/05 and A/Chicken/Vietnam/486A/04)
that carried these NA mutations and had reduced NA inhibitor
susceptibility. Conversely, A/WSN/33 (H1N1) virus with the
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discrepancy in observed phenotype may be explained by usage of
different N1 NA proteins of H1N1 and H5N1 viruses and/or to
specific changes in different N1 antigens. Our study is the first to
our knowledge to fully elucidate the role of the V116A and I117V
NA amino acid substitutions in NA inhibitor resistance in a
genetically homogeneous H5N1-virus background in the absence
of concomitant HA and/or NA mutations. Importantly, residues
116 and 117 are fully conserved in group 1 NA glycoproteins (N1,
N4, N5, and N8 [29]), and their location adjacent to R118 may
affect one of the three arginine residues that bind the carboxylate
of the substrate sialic acid with further effect on virus susceptibility
to the anti-NA drugs [29].
We also confirmed previous findings that the presence of
histidine at position 252 in recent H5N1 isolates is associated with
increased affinity of their NAs for oseltamivir carboxylate
[11,18,34]. In clade 1 NAs, this residue is normally H252, but
in clade 2 NAs it is consistently Y252. Because this mutation
Figure 4. Replication of recombinant WT, E119A, and N294S viruses in internal organs and histologic changes in the lungs
morphology of ferrets infected with these H5N1 viruses. (A) Virus titers were determined for the lungs (4 lobes tested separately), nasal
turbinates, tracheas, small intestines, and livers of ferrets on day 4 post-inoculation. Values (log10EID50/gram tissue) are the mean 6 s.d. for two
ferrets, unless it is indicated that the virus was detected in one of two ferrets. *, P,0.05, **, P,0.01 compared to WT virus (one-way ANOVA). (B) The
images shown are hematoxylin-and-eosin-stained sections of lung tissue from ferrets inoculated with the WT, E119A, and N294S viruses obtained on
day 4 post-inoculation. Lung showing bronchiole (b) with epithelial necrosis, intraluminal debris, and inflammatory cells. Lung alveoli (a) of the WT-
infected ferrets are lined with interstitial septa (arrows) and have mild to moderate inflammatory cell infiltrates. The lung alveolar architecture of the
ferrets inoculated with the E119A mutant is lost due to necrosis of alveolar pneumocytes and the interstitial septa. Lung alveoli of the N294S-infected
ferrets are filled with inflammatory cells and hyperplastic pneumocytes obscuring interstitial septa. Magnification, 620.
doi:10.1371/journal.ppat.1000933.g004
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oseltamivir, we speculate that genetic variation in highly
pathogenic clade 2 H5N1 viruses in the absence of drug-selective
pressure may reduce oseltamivir susceptibility in vitro (15- to 30-
fold differences in IC50 values) [11] and in vivo [9].
We studied the pathogenicity and virulence of the NA-mutant
H5N1 influenza viruses in ferrets, an acceptable animal model to
evaluate influenza virus disease manifestations [35]. The inefficient
transmissibility of H5N1 influenza viruses in these mammals [36]
(as in humans) restricted our studies to evaluation of pathogenicity.
Importantly, recombinant H5N1 viruses carrying framework NA
mutations (E119A and N294S) were more virulent and were
associated with significantly higher virus titers in the lungs and
liver than WT virus (P,0.01). The molecular basis of this finding
is unknown. However, the possibility that after exposure to one
NA inhibitor the chance exists that occurring drug-resistant H5N1
mutant could be cross resistant to both antiviral drugs and will be
more virulent that the WT virus (like E119A H5N1 recombinant
virus) should prompt to re-assess the suitability of single-drug
usage. None of the NA mutations studied resulted in decreased
viral virulence in the ferret animal model, consistent with our
group’s previous finding that NA inhibitor-resistant mutations did
not impair the virulence of clade 1 A/Vietnam/1203/04 (H5N1)
virus in mice [24]. Here we used A/Turkey/15/06 (H5N1) virus
belonging to clade 2.2, whose virulence is lower than that of the
A/Vietnam/1203/04 (H5N1) strain [10]. Its NA activity is lower
as well but is higher than that of current seasonal human-like N1
NAs even in the presence of drug-resistant NA mutations (data not
shown). Therefore, taken together, our results showed that the
virulence of H5N1 influenza viruses does not seem to be decreased
by the NA-inhibitor resistant mutations studied here. We did not
observe a consistent pattern in the effect of enzyme kinetics (Vmax
and Km) on virulence in ferrets. None of the recombinant mutants
exhibited an increased affinity for the substrate and a higher
activity compared to WT NA, which could possibly indicate their
overall better fitness. However, recombinant H5N1 viruses
carrying I117V and Y252H NA mutations possessed the highest
relative NA activity, but ferrets infected with these viruses
experienced a mild, brief illness. Additional studies are needed
to identify the impact of NA activity and affinity on the duration of
influenza disease in vivo.
Our data demonstrate the significance of continued character-
ization of all H5N1 isolates for susceptibility to NA inhibitors in
order to identify novel NA markers of altered susceptibility. We
believe that this knowledge is essential for planning appropriate
management strategies for a future pandemic. It is noteworthy that
alignment of the NA genes of currently circulating highly
pathogenic H5N1 influenza A viruses identified the NA mutations
studied here in ,0.1%–1.4% of isolates (namely, I117V was found
in 1.4% and V116A and I119A were found in 0.1% isolates),
raising concern about the drug sensitivity of a possible pandemic
strain. Future studies should focus on the establishment of novel
antiviral strategies to minimize the emergence of resistance.
Materials and Methods
Ethics Statement
All animal experiments with recombinant H5N1 influenza
viruses were performed in biosafety level 3+ facilities at St. Jude
Children’s Research Hospital (St. Jude; Memphis, TN, USA). All
animal studies were approved by the St. Jude Children’s Research
Hospital Animal Care and Use Committee and were conducted
according to applicable laws and guidelines.
Cells, Viruses and Compounds
Madin-Darby canine kidney (MDCK) and human embryonic
kidney (293T) cells were obtained from the American Type
Culture Collection and maintained as previously described [24].
Eight plasmids were constructed from the DNA sequences of
the 8 gene segments of wild-type A/Turkey/15/06 (H5N1) virus
for the reverse-genetics generation of recombinant wild-type virus.
Recombinant virus was generated by DNA transfection of 293T
cells [37], and the point mutations (Table 1, Figure 1) were
inserted into the NA gene of wild-type virus by using a
Quickchange site-directed mutagenesis kit (Stratagene) [24]. Stock
viruses were prepared in MDCK cells at 37uC for 72 h and their
entire HA and NA genes were sequenced to verify the presence of
the mutations. The recombinant viruses were designated accord-
ing to their NA mutations (Table 1, Figure 1). All experimental
work with the H5N1 recombinant viruses was performed in a
biosafety level 3+ laboratory approved for use by the U.S.
Department of Agriculture and the U.S. Centers for Disease
Control and Prevention.
The NA inhibitors oseltamivir carboxylate (oseltamivir)
([3R,4R,5S]-4-acetamido-5-amino-3-[1-ethylpropoxy]-1-cyclohex-
ene-1-carboxylic acid) and zanamivir (4-guanidino-Neu5Ac2en)
were provided by Hoffmann-La Roche, Ltd.
Stability and Infectivity of Recombinant H5N1 Viruses
The genetic stability of the viruses was monitored by sequencing
of the HA and NA genes after transfection and after three passages
in MDCK cells at a MOI of 0.001 PFU/ml. If different
subpopulations were identified, those viruses were considered
unstable.
The infectivity of recombinant H5N1 viruses was determined in
MDCK cells by plaque assay and expressed as log10PFU/ml [9].
Briefly, confluent MDCK cells were incubated at 37uC for 1 h
with 10-fold serial dilutions of virus. The cells were then washed
and overlaid with minimal essential medium containing 0.3%
bovine serum albumin and 0.9% Bacto agar and incubated at
37uC for 72 h. The plaques were stained with 0.1% crystal violet
solution containing 10% formaldehyde, and virus yield was
determined. Plaque diameter of any 10 plaques was measured
by the FinescaleH comparator (Los Angeles, CA, USA).
NA Enzyme Activity and Kinetics
Modified fluorometric assay was used to determine the NA
activity of the recombinant H5N1 viruses [38]. We measured the
NA enzyme kinetics at pH 6.5 with 33 mM 2-(N-Morpholi-
no)ethanesulfonic acid hydrate (MES; Sigma-Aldrich), 4 mM
CaCl2, and fluorogenic substrate 2’-(4-methylumbelliferyl)-a-D-
N-acetylneuraminic acid (MUNANA; Sigma-Aldrich; final sub-
strate concentration, 0–2000 mM). All H5N1 viruses were
standardized to an equivalent dose of 10
7.5 PFU/ml. The reaction
was conducted at 37uC in a total volume of 50 ml, and the
fluorescence of released 4-methylumbelliferone was measured
every 92 sec for 45 min in a Fluoroskan II instrument (Labsystems)
using excitation and emission wavelengths of 355 and 460 nm,
respectively. To measure the inhibitory effect of oseltamivir
carboxylate or zanamivir on NA activity, H5N1 viruses were
preincubated for 30 min at 37uC in the presence of various
concentrations of the drugs (0.00005–5 mM). The kinetic param-
eters Michaelis-Menten constant (Km), maximum velocity of
substrate conversion (Vmax), and inhibitory constant (Ki) of the
NAs were calculated by fitting the data to the appropriate
Michaelis-Menten equations by using nonlinear regression in the
commercially available GraphPad Prism 4 software (GraphPad
Software, La Jolla, CA).
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Recombinant H5N1 viruses were standardized to equivalent
NA activity and incubated for 30 min at 37uC with NA inhibitors
at concentrations of 0.00005–100 mM with MUNANA (Sigma-
Aldrich) as a substrate. After 1 h, the reaction was terminated by
adding 14 mM NaOH and fluorescence was quantified in a
Fluoroskan II (Labsystems) fluorometer. The concentration of NA
inhibitor that reduced NA activity by 50% relative to a control
mixture with no inhibitor (IC50) was determined by plotting the
dose-response curve of inhibition of NA activity as a function of
the compound concentration. Values are the mean of 2–3
independent determinations.
Assessment of Virus Pathogenicity in Ferrets
Pathogenicity was tested in 4- to 5-month-old male ferrets obtained
through the ferret breeding program at St. Jude Children’s Research
Hospital or from Marshall Farms (North Rose, NY). All ferrets were
seronegative for influenza A H1N1, H3N2, and H5N1, and for
influenza B viruses. Groups of three ferrets were inoculated intranasally
under light isoflurane anesthesia with 10
6 EID50 of virus in 1 ml sterile
phosphate-buffered saline (PBS). Clinical signs of infection, relative
inactivity index [35], weight, and temperature were recorded daily.
Activity level was assessed by using the following scoring system: 0, alert
and playful; 1, alert but playful when stimulated; 2, alert but not playful
when stimulated; and 3, neither alert nor playful when stimulated. The
relative inactivity index was calculated as the mean score per group of
ferrets per observation (day) over the 14-day period. Animals that
showed signs of severe disease (respiratory signs [labored breezing,
sneezing, wheezing, and nasal discharge], febrility, lethargy, steady
weight loss, and neurological signs [hind-limb paresis, ataxia, torticollis,
and tremor] and .25% weight loss were euthanized. Body
temperature was measured by subcutaneous implantable temperature
transponders (Bio Medic Data Systems Inc.).
To monitor virus shedding, nasal washes were collected from
ferrets on days 1, 2, 4, 6, and 8 post-challenge. Virus was titrated
in 10-day old embryonated chicken eggs by injecting 0.1 ml of
serial 10-fold dilutions of the sample (three eggs per dilution) and
expressed as log10EID50/ml. Inflammatory cell counts and protein
concentrations in nasal washes were determined as described
previously [39]. Briefly, the nasal washes were centrifuged at 2,000
rpm for 10 min. The cell pellet was resuspended in PBS, and the
cells were counted microscopically in a hemacytometer. The total
number of inflammatory cells was calculated on the basis of the
initial volume of nasal wash. The protein concentration in cell-free
nasal washes was measured by using a protein reagent from Bio-
Rad (Hercules).
Titration of Virus in Organs
Two animals inoculated with WT, E119A, or N294S viruses
were euthanized by intracardiac injection of Euthanasia V solution
on day 4 post-inoculation, and tissue samples (,0.5 g each) were
collected from lungs (4 lobes tested separately), nasal turbinate,
trachea, spleen, liver, and small intestine. Samples were homog-
enized in 1 ml sterile PBS with antibiotics, and the virus titer
(log10EID50/gram tissue) was determined in 10-day old embryo-
nated chicken eggs.
Histopathologic Analysis
Tissues (lung, nasal turbinate, trachea, spleen, liver, and small
intestine) were collected at the time of necropsy, fixed in 10%
neutral-buffered formalin, and embedded in paraffin. Five-
micrometer-thick sections were stained with hematoxylin and
eosin and studied by light microscopy.
Serologic Tests
Serum samples were collected from ferrets 3 weeks after
inoculation, treated with receptor-destroying enzyme, heat-
inactivated at 56 uC for 30 min, and tested by hemagglutination
inhibition (HI) assay with 0.5% packed chicken red blood cells by a
standard method as described previously [40].
Virus Sequence Analysis
Viral RNAs were isolated from virus-containing cell culture
fluid after transfection, after three passages in MDCK cells or from
ferret nasal washes by using the RNeasy Mini kit (Qiagen).
Samples were reverse-transcribed and analyzed by PCR using
universal primers specific for the HA and NA gene segments, as
described previously [41]. Sequencing was performed by the
Hartwell Center for Bioinformatics and Biotechnology at St. Jude.
The DNA template was sequenced by using rhodamine or
dRhodamine dye terminator cycle-sequencing Ready Reaction
kits with AmpliTaq DNA polymerase FS (Perkin-Elmer) and
synthetic oligonucleotides. Samples were analyzed in a Perkin-
Elmer Applied Biosystems DNA sequencer (model 373 or 377).
DNA sequences were completed and edited by using the
Lasergene sequence analysis software package (DNASTAR).
Statistical Analysis
The virus yield, plaque size, NA inhibitor susceptibility, NA
enzyme kinetic parameters (Km,V max,K i), virus titers in ferret
organs and nasal wash samples, differences in fevers, weights, total
number of cells and protein concentrations in nasal wash samples,
mean survival time, and relative inactivity index of ferrets
inoculated with wild-type and mutant viruses were compared by
analysis of variance (ANOVA). Virus yields and plaque size of
recombinant H5N1 viruses after the first and the third passage in
MDCK cells were compared by unpaired two-tailed t-test. The
probability of survival was estimated by the Kaplan-Meier method
and compared between groups of ferrets by using the log-rank
(Mantel-Haenszel) test [42]. A probability value of 0.05 was
prospectively chosen to indicate that the findings were not the
result of chance alone.
Supporting Information
Figure S1 Patterns of clinical outcome in ferrets inoculated with
recombinant WT, E119A and N294S viruses. Shown are change in
body temperature and weight, total number of inflammatory cells
and protein concentrations in nasal washes, and virus titers in the
upper respiratory tract. The horizontal lines show the mean
inflammatory cell counts and protein concentrations in the nasal
washes of uninoculated animals. Values are the mean 6 s.d. for five
(orthree ondays6and8 p.i.)ferrets.Themeans.d.ofalldata points
for change in body temperature and weight was ,64.5%. *, P ,
0.05, **, P , 0.01 compared to WT virus (one-way ANOVA).
Found at: doi:10.1371/journal.ppat.1000933.s001 (0.48 MB TIF)
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